MX352024B - Formulaciones potentes de liberacion controlada. - Google Patents

Formulaciones potentes de liberacion controlada.

Info

Publication number
MX352024B
MX352024B MX2014006625A MX2014006625A MX352024B MX 352024 B MX352024 B MX 352024B MX 2014006625 A MX2014006625 A MX 2014006625A MX 2014006625 A MX2014006625 A MX 2014006625A MX 352024 B MX352024 B MX 352024B
Authority
MX
Mexico
Prior art keywords
low viscosity
compositions
forming
acyl
release formulations
Prior art date
Application number
MX2014006625A
Other languages
English (en)
Other versions
MX2014006625A (es
Inventor
Tiberg Fredrik
Johnsson Markus
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47226199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX352024(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of MX2014006625A publication Critical patent/MX2014006625A/es
Publication of MX352024B publication Critical patent/MX352024B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)

Abstract

La presente invención se relaciona con composiciones que forman una mezcla de baja viscosidad de: a. al menos un diacilglicerol y/o al menos un tecoferol; b. al menos un componente fosfolípido que comprende fosfolípidos que tienen, i. grupos de cabeza polar que comprenden más de un 50% de fosfatidiletanolamina, y ii. Dos cadenas de acilo, cada una tiene independientemente de 16 a 20 carbonos, donde al menos una cadena de acilo tiene al menos una insaturación en la cadena de carbono, y no existen más de cuatro insaturaciones en dos cadenas de carbono; c. al menos un solvente orgánico biocompatible, de baja viscosidad, que contiene oxígeno; donde, opcionalmente, se disuelve o dispersa al menos un agente bioactivo en la mezcla de baja viscosidad; y donde la predormulación forma, o tiene la capacidad de formar, al menos una estructura de fase cristalina líquida no laminar al contacto con un fluido acuoso. La invención se relaciona adicionalmente con métodos de tratamiento que comprenden la administración de tales composiciones y con dispositivos de administración precargados y kits que contienen las formulaciones.
MX2014006625A 2011-12-05 2012-11-28 Formulaciones potentes de liberacion controlada. MX352024B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566851P 2011-12-05 2011-12-05
PCT/EP2012/073843 WO2013083460A1 (en) 2011-12-05 2012-11-28 Robust controlled-release formulations

Publications (2)

Publication Number Publication Date
MX2014006625A MX2014006625A (es) 2014-09-22
MX352024B true MX352024B (es) 2017-11-07

Family

ID=47226199

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014006625A MX352024B (es) 2011-12-05 2012-11-28 Formulaciones potentes de liberacion controlada.
MX2014006624A MX350929B (es) 2011-12-05 2012-11-28 Formulaciones peptidicas robustas de liberación controlada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014006624A MX350929B (es) 2011-12-05 2012-11-28 Formulaciones peptidicas robustas de liberación controlada.

Country Status (22)

Country Link
US (2) US9585959B2 (es)
EP (2) EP2787975B1 (es)
JP (2) JP6081479B2 (es)
KR (2) KR101979051B1 (es)
CN (2) CN104093399B (es)
AU (2) AU2012348640B2 (es)
BR (2) BR112014013693B1 (es)
CA (2) CA2857982A1 (es)
CL (1) CL2014001472A1 (es)
CO (1) CO7000746A2 (es)
DK (2) DK2787975T3 (es)
EA (2) EA027924B1 (es)
ES (2) ES2629188T3 (es)
HR (1) HRP20170954T1 (es)
IL (2) IL232789B (es)
MX (2) MX352024B (es)
PE (1) PE20141297A1 (es)
PL (1) PL2787975T3 (es)
SG (1) SG11201402673YA (es)
SI (1) SI2787974T1 (es)
WO (2) WO2013083460A1 (es)
ZA (1) ZA201403793B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
PE20141484A1 (es) * 2011-05-25 2014-10-31 Camurus Ab Formulaciones peptidicas de liberacion controlada
ES2834318T3 (es) 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
EP3045162B1 (en) 2012-07-26 2021-07-07 Camurus AB Opioid formulations
SG11201500554XA (en) 2012-07-26 2015-02-27 Camurus Ab Opioid formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
CN106232131A (zh) 2013-10-22 2016-12-14 普洛林克斯有限责任公司 生长抑素和其类似物的结合物
US10722462B2 (en) 2014-12-10 2020-07-28 Council Of Scientific And Industrial Research Discontinuous reverse micellar composition in cubic FD3M phase for sustained release of therapeutic drugs
CA2971642A1 (en) * 2014-12-23 2016-06-30 Camurus Ab Controlled-release formulations
GB201516554D0 (en) * 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
ITUB20160416A1 (it) * 2016-01-28 2017-07-28 Italfarmaco Spa Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma
CN108883157A (zh) * 2016-03-31 2018-11-23 太阳医药高级研发有限公司 适用于每周一次或每两周一次给药的利拉鲁肽的粘弹性凝胶
WO2018050864A1 (en) * 2016-09-15 2018-03-22 Camurus Ab Prostacyclin analogue formulations
AU2017336199B2 (en) * 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
WO2018217926A1 (en) 2017-05-24 2018-11-29 Vmr Products Llc Flavor disk
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
EP3787611A4 (en) 2018-05-01 2022-03-09 Chibi, Inc. LIQUID DEPOT FOR NONINVASIVE DELAYED DELIVERY OF DRUGS TO THE EYE
CA3097926A1 (en) * 2018-05-01 2019-11-07 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
CN108498849B (zh) * 2018-05-08 2021-04-30 武汉百纳礼康生物制药有限公司 一种液晶凝胶肝动脉栓塞剂及其制备方法
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
MX2021014450A (es) 2019-05-29 2022-01-06 Camurus Ab Composiciones de liberacion controlada de lipidos.
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
AU2021299156C1 (en) * 2020-06-30 2025-02-06 Chong Kun Dang Pharmaceutical Corp. Injectable composition comprising GnRH analogue
WO2022093722A1 (en) * 2020-10-27 2022-05-05 Pts Consulting, Llc A liquid injectable composition of donepezil
CN113081954A (zh) * 2021-05-25 2021-07-09 南昌大学第二附属医院 一种凝胶载药贴剂药物输送系统
EP4378452A4 (en) * 2021-07-27 2025-07-23 Farnex Incorporated NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION AND ITS USE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
ES2135723T3 (es) * 1994-03-30 1999-11-01 Gs Dev Ab Uso de esteres de acidos grasos como sustancias bioadhesivas.
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
WO2005039642A1 (en) * 2003-10-24 2005-05-06 University Of Saskatchewan Dna delivery with gemini cationic surfactants
AU2005324794C1 (en) * 2003-11-07 2010-12-02 Camurus Ab Somatostatin analogue formulations
EP1682091B1 (en) * 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
CA2554052C (en) 2004-01-23 2013-10-22 Camurus Ab Ternary non-lamellar lipid compositions of structure forming amphiphile, structure swelling amphiphile and dispersion stabilising amphiphile
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
WO2006002050A1 (en) * 2004-06-15 2006-01-05 Encore Therapeutics, Inc. Phospholipid compositions and methods for their preparation and use
EP1848403B8 (en) 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
KR101245022B1 (ko) 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
DK1888031T3 (da) 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations

Also Published As

Publication number Publication date
EP2787974B1 (en) 2017-05-24
JP2015500253A (ja) 2015-01-05
AU2012348641B2 (en) 2016-04-21
SG11201402673YA (en) 2014-06-27
CL2014001472A1 (es) 2014-11-21
SI2787974T1 (sl) 2017-10-30
US9585959B2 (en) 2017-03-07
CN104093399A (zh) 2014-10-08
CN104093399B (zh) 2018-03-13
KR20140105527A (ko) 2014-09-01
US9555118B2 (en) 2017-01-31
US20140329749A1 (en) 2014-11-06
CA2857982A1 (en) 2013-06-13
CA2858227C (en) 2021-01-05
AU2012348641A1 (en) 2014-06-19
CN104105479A (zh) 2014-10-15
DK2787975T3 (da) 2017-11-20
HK1201722A1 (en) 2015-09-11
JP2015505833A (ja) 2015-02-26
IL232789A0 (en) 2014-07-31
EA027924B1 (ru) 2017-09-29
AU2012348640B2 (en) 2016-07-21
US20140348903A1 (en) 2014-11-27
CN104105479B (zh) 2018-04-10
PE20141297A1 (es) 2014-10-09
DK2787974T3 (en) 2017-07-17
MX350929B (es) 2017-09-26
BR112014013693A2 (pt) 2020-06-30
JP6081480B2 (ja) 2017-02-15
WO2013083460A1 (en) 2013-06-13
MX2014006625A (es) 2014-09-22
KR101979051B1 (ko) 2019-05-15
EP2787975A1 (en) 2014-10-15
MX2014006624A (es) 2014-09-22
HRP20170954T1 (hr) 2017-09-22
KR20140111661A (ko) 2014-09-19
WO2013083459A1 (en) 2013-06-13
EA028040B1 (ru) 2017-09-29
CO7000746A2 (es) 2014-07-21
BR112014013693B1 (pt) 2023-01-31
EP2787975B1 (en) 2017-10-04
PL2787975T3 (pl) 2018-01-31
ES2645345T3 (es) 2017-12-05
JP6081479B2 (ja) 2017-02-15
HK1201735A1 (en) 2015-09-11
ZA201403793B (en) 2017-04-26
ES2629188T3 (es) 2017-08-07
AU2012348640A1 (en) 2014-07-17
EP2787974A1 (en) 2014-10-15
CA2858227A1 (en) 2013-06-13
BR112014013691A2 (pt) 2017-06-13
IL232967A0 (en) 2014-07-31
EA201491005A1 (ru) 2014-11-28
EA201490921A1 (ru) 2014-11-28
IL232789B (en) 2019-11-28

Similar Documents

Publication Publication Date Title
MX352024B (es) Formulaciones potentes de liberacion controlada.
MX2013013401A (es) Formulaciones pepticidas de liberacion controlada.
ECSP14012527A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
PE20180203A1 (es) Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
MX2018003333A (es) Formulaciones de liberacion controlada.
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
ATE401054T1 (de) Flüssige depotformulierungen
PE20130230A1 (es) Derivados de carboxamidas n-azabiciclicas y su preparacion
EA201291108A1 (ru) Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
RU2014144501A (ru) Депо-составы гидрофобного активного ингредиента и способы их получения
AR081535A1 (es) Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
AR122269A1 (es) Uso de ésteres de poliglicerol como vehículo para ingredientes microbiológicos activos
TN2014000483A1 (en) Somatostatin receptor agonist formulations
CR11823A (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenarativas e inflamatorias
ATE501710T1 (de) Somatostatin-analog-formulierungen
PE20081491A1 (es) Composicion farmaceutica que comprende (r)-5,6-dimetoxi-2-[2,2,4,6,7-pentametil-3-(4-metilfenil)-2,3-dihidro-1-benzofuran-5-il)isoindolina y un componente lipofilico
ECSP10010663A (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenarativas e inflamatorias
RU2012127261A (ru) Фармацевтическая композиция хондропротекторов для трансдермального применения
AR084411A1 (es) SUSPOEMULSION ACUOSA QUE CONTIENE LUFENURON Y l-CIHALOTRINA Y PROCEDIMIENTO PARA PREPARARLA

Legal Events

Date Code Title Description
FG Grant or registration